| Literature DB >> 27238972 |
Jingwei Gao1, Kun Zhang1, Jie Chen2, Mong-Heng Wang3, Jingfeng Wang1, Pinming Liu1, Hui Huang4.
Abstract
Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.Entities:
Keywords: Aldosterone; Genomic mechanisms; Non-genomic mechanisms; Vascular calcification; Vascular smooth muscle cells
Mesh:
Substances:
Year: 2016 PMID: 27238972 DOI: 10.1016/j.ejphar.2016.05.030
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432